-
Je něco špatně v tomto záznamu ?
Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome
B. Wolska-Kusnierz, A. Pastorczak, W. Fendler, A. Wakulinska, B. Dembowska-Baginska, E. Heropolitanska-Pliszka, B. Piątosa, B. Pietrucha, K. Kałwak, M. Ussowicz, A. Pieczonka, K. Drabko, M. Lejman, S. Koltan, J. Gozdzik, J. Styczynski, A....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
NLK
Free Medical Journals
od 1995 do Před 1 rokem
Freely Accessible Science Journals
od 1995
Open Access Digital Library
od 1995-01-01
Open Access Digital Library
od 1995-01-01
- MeSH
- dítě MeSH
- dospělí MeSH
- incidence MeSH
- Kaplanův-Meierův odhad MeSH
- kohortové studie MeSH
- komorbidita MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- nádory epidemiologie terapie MeSH
- následné studie MeSH
- prevalence MeSH
- syndrom Nijmegen breakage epidemiologie MeSH
- transplantace hematopoetických kmenových buněk metody MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Polsko MeSH
PURPOSE: Nijmegen breakage syndrome (NBS) is a DNA repair disorder with a high predisposition to hematologic malignancies. EXPERIMENTAL DESIGN: We describe the natural history of NBS, including cancer incidence, risk of death, and the potential effectiveness of hematopoietic stem cell transplantation (HSCT) in preventing both pathologies: malignancy and immunodeficiency. RESULTS: Among 241 patients with NBS enrolled in the study from 11 countries, 151 (63.0%) patients were diagnosed with cancer. Incidence rates for primary and secondary cancer, tumor characteristics, and risk factors affecting overall survival (OS) were estimated. The cumulative cancer incidence was 40.21% ± 3.5% and 77.78% ± 3.4% at 10 years and 20 years of follow-up, respectively. Most of the tumors n = 95 (62.9%) were non-Hodgkin lymphomas. Overall, 20 (13.2%) secondary malignancies occurred at a median age of 18 (interquartile range, 13.7-21.5) years. The probability of 20-year overall survival (OS) for the whole cohort was 44.6% ± 4.5%. Patients who developed cancer had a shorter 20-year OS than those without malignancy (29.6% vs. 86.2%; P < 10-5). A total of 49 patients with NBS underwent HSCT, including 14 patients transplanted before malignancy. Patients with NBS with diagnosed cancer who received HSCT had higher 20-year OS than those who did not (42.7% vs. 30.3%; P = 0.038, respectively). In the group of patients who underwent preemptive transplantation, only 1 patient developed cancer, which is 6.7 times lower as compared with nontransplanted patients [incidence rate ratio 0.149 (95% confidence interval, 0.138-0.162); P < 0.0001]. CONCLUSIONS: There is a beneficial effect of HSCT on the long-term survival of patients with NBS transplanted in their first complete remission of cancer.
Belarusian Research Center for Pediatric Oncology and Hematology Minsk Belarus
Department of Biostatistics and Translational Medicine Medical University of Lodz Lodz Poland
Department of Hematology Oncology and Internal Medicine Medical University of Warsaw Warsaw Poland
Department of Immunology Children's Memorial Health Institute Warsaw Poland
Department of Medical Genetics The Children's Memorial Health Institute Warsaw Poland
Department of Oncology Children's Memorial Health Institute Warsaw Poland
Department of Pediatric Hematology and Oncology Oslo University Hospital Oslo Norway
Department of Pediatric Hematology and Oncology University Hospital Heidelberg Germany
Department of Pediatric Hematology Oncology and Transplantology Medical University of Lublin Poland
Department of Pediatric Oncology Poznan University of Medical Sciences Poznan Poland
Department of Pediatrics Hannover Medical School Hannover Germany
Department of Radiation Oncology Dana Farber Cancer Institute Boston Massachusetts
Department Pediatrics Oncology and Hematology Medical University of Lodz Lodz Poland
Dr von Hauner University Children's Hospital Ludwig Maximilians University Munich Germany
Great Ormond Street Hospital for Children NHS Foundation Trust London United Kingdom
Histocompatibility Laboratory Children's Memorial Health Institute Warsaw Poland
Pediatric Department St Olav University Hospital Trondheim Norway
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012538
- 003
- CZ-PrNML
- 005
- 20220506125836.0
- 007
- ta
- 008
- 220425s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1158/1078-0432.CCR-20-2574 $2 doi
- 035 __
- $a (PubMed)33082212
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Wolska-Kusnierz, Beata $u Department of Immunology, Children's Memorial Health Institute, Warsaw, Poland
- 245 10
- $a Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome / $c B. Wolska-Kusnierz, A. Pastorczak, W. Fendler, A. Wakulinska, B. Dembowska-Baginska, E. Heropolitanska-Pliszka, B. Piątosa, B. Pietrucha, K. Kałwak, M. Ussowicz, A. Pieczonka, K. Drabko, M. Lejman, S. Koltan, J. Gozdzik, J. Styczynski, A. Fedorova, N. Miakova, E. Deripapa, L. Kostyuchenko, Z. Krenova, E. Hlavackova, AR. Gennery, KW. Sykora, S. Ghosh, MH. Albert, D. Balashov, M. Eapen, P. Svec, MG. Seidel, SS. Kilic, A. Tomaszewska, E. Wiesik-Szewczyk, A. Kreins, J. Greil, J. Buechner, B. Lund, H. Gregorek, K. Chrzanowska, W. Mlynarski
- 520 9_
- $a PURPOSE: Nijmegen breakage syndrome (NBS) is a DNA repair disorder with a high predisposition to hematologic malignancies. EXPERIMENTAL DESIGN: We describe the natural history of NBS, including cancer incidence, risk of death, and the potential effectiveness of hematopoietic stem cell transplantation (HSCT) in preventing both pathologies: malignancy and immunodeficiency. RESULTS: Among 241 patients with NBS enrolled in the study from 11 countries, 151 (63.0%) patients were diagnosed with cancer. Incidence rates for primary and secondary cancer, tumor characteristics, and risk factors affecting overall survival (OS) were estimated. The cumulative cancer incidence was 40.21% ± 3.5% and 77.78% ± 3.4% at 10 years and 20 years of follow-up, respectively. Most of the tumors n = 95 (62.9%) were non-Hodgkin lymphomas. Overall, 20 (13.2%) secondary malignancies occurred at a median age of 18 (interquartile range, 13.7-21.5) years. The probability of 20-year overall survival (OS) for the whole cohort was 44.6% ± 4.5%. Patients who developed cancer had a shorter 20-year OS than those without malignancy (29.6% vs. 86.2%; P < 10-5). A total of 49 patients with NBS underwent HSCT, including 14 patients transplanted before malignancy. Patients with NBS with diagnosed cancer who received HSCT had higher 20-year OS than those who did not (42.7% vs. 30.3%; P = 0.038, respectively). In the group of patients who underwent preemptive transplantation, only 1 patient developed cancer, which is 6.7 times lower as compared with nontransplanted patients [incidence rate ratio 0.149 (95% confidence interval, 0.138-0.162); P < 0.0001]. CONCLUSIONS: There is a beneficial effect of HSCT on the long-term survival of patients with NBS transplanted in their first complete remission of cancer.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a komorbidita $7 D015897
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a transplantace hematopoetických kmenových buněk $x metody $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a nádory $x epidemiologie $x terapie $7 D009369
- 650 _2
- $a syndrom Nijmegen breakage $x epidemiologie $7 D049932
- 650 _2
- $a prevalence $7 D015995
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a Polsko $x epidemiologie $7 D011044
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pastorczak, Agata $u Department Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland
- 700 1_
- $a Fendler, Wojciech $u Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland $u Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
- 700 1_
- $a Wakulinska, Anna $u Department of Oncology, Children's Memorial Health Institute, Warsaw, Poland $1 https://orcid.org/0000000225610636
- 700 1_
- $a Dembowska-Baginska, Bozena $u Department of Oncology, Children's Memorial Health Institute, Warsaw, Poland
- 700 1_
- $a Heropolitanska-Pliszka, Edyta $u Department of Immunology, Children's Memorial Health Institute, Warsaw, Poland
- 700 1_
- $a Piątosa, Barbara $u Histocompatibility Laboratory, Children's Memorial Health Institute, Warsaw, Poland $1 https://orcid.org/000000018949047X
- 700 1_
- $a Pietrucha, Barbara $u Department of Immunology, Children's Memorial Health Institute, Warsaw, Poland
- 700 1_
- $a Kałwak, Krzysztof $u Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
- 700 1_
- $a Ussowicz, Marek $u Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland $1 https://orcid.org/0000000157254835
- 700 1_
- $a Pieczonka, Anna $u Department of Pediatric Oncology, Poznan University of Medical Sciences, Poznan, Poland $1 https://orcid.org/0000000159224242
- 700 1_
- $a Drabko, Katarzyna $u Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, Poland $1 https://orcid.org/0000000270949129
- 700 1_
- $a Lejman, Monika $u Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, Poland $1 https://orcid.org/0000000287600775
- 700 1_
- $a Koltan, Sylwia $u Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland $1 https://orcid.org/0000000176636580
- 700 1_
- $a Gozdzik, Jolanta $u Department of Transplantation, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland $1 https://orcid.org/0000000254490266
- 700 1_
- $a Styczynski, Jan $u Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland
- 700 1_
- $a Fedorova, Alina $u Belarusian Research Center for Pediatric Oncology and Hematology, Minsk, Belarus $1 https://orcid.org/0000000215598223
- 700 1_
- $a Miakova, Natalia $u Department of Pediatric Oncology and Hematology, Federal Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
- 700 1_
- $a Deripapa, Elena $u Department of Immunology and Hematopoietic Stem Cell Transplantation, Federal Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia $1 https://orcid.org/0000000290834783
- 700 1_
- $a Kostyuchenko, Larysa $u Department of Pediatric Immunology, Western Ukrainian Specialized Children's Medical Centre, Lviv, Ukraine
- 700 1_
- $a Krenova, Zdenka $u Department of Pediatric Oncology, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Hlavackova, Eva $u Department of Pediatric Oncology, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Clinical Immunology and Allergology, St. Anne's University Hospital in Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000286107540
- 700 1_
- $a Gennery, Andrew R $u Translational and Clinical Research Institute, Newcastle University and Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom $1 https://orcid.org/0000000262181324
- 700 1_
- $a Sykora, Karl-Walter $u Department of Pediatrics, Hannover Medical School (MHH), Hannover, Germany
- 700 1_
- $a Ghosh, Sujal $u Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-University, Düsseldorf, Germany
- 700 1_
- $a Albert, Michael H $u Dr. von Hauner University Children's Hospital, Ludwig-Maximilians-University, Munich, Germany
- 700 1_
- $a Balashov, Dmitry $u Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia
- 700 1_
- $a Eapen, Mary $u Center for International Blood and Marrow Transplant, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
- 700 1_
- $a Svec, Peter $u Department of Pediatric Hematology and Oncology, Comenius University and National Institute of Children's Diseases, Bratislava, Slovakia $1 https://orcid.org/0000000276472253
- 700 1_
- $a Seidel, Markus G $u Research Unit Pediatric Hematology and Immunology, Division of Pediatric Hematology-Oncology, Department of Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria $1 https://orcid.org/0000000309818661
- 700 1_
- $a Kilic, Sara S $u Pediatric Immunology Division, Department of Pediatrics, Uludag University Medical Faculty, Bursa, Turkey
- 700 1_
- $a Tomaszewska, Agnieszka $u Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000154853680
- 700 1_
- $a Wiesik-Szewczyk, Ewa $u Department of Internal Medicine, Pneumonology, Allergology and Clinical Immunology, Central Clinical Hospital of the Ministry of National Defense, Military Institute of Medicine, Warsaw, Poland $1 https://orcid.org/0000000185094453
- 700 1_
- $a Kreins, Alexandra $u Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom $1 https://orcid.org/0000000187485837
- 700 1_
- $a Greil, Johann $u Department of Pediatric Hematology and Oncology, University Hospital, Heidelberg, Germany
- 700 1_
- $a Buechner, Jochen $u Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway $1 https://orcid.org/0000000158484501
- 700 1_
- $a Lund, Bendik $u Pediatric Department, St Olav University Hospital, Trondheim, Norway
- 700 1_
- $a Gregorek, Hanna $u Department of Microbiology and Clinical Immunology, The Children's Memorial Health Institute, Warsaw, Poland
- 700 1_
- $a Chrzanowska, Krystyna $u Department of Medical Genetics, The Children's Memorial Health Institute, Warsaw, Poland
- 700 1_
- $a Mlynarski, Wojciech $u Department Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland. wojciech.mlynarski@umed.lodz.pl
- 773 0_
- $w MED00001121 $t Clinical cancer research : an official journal of the American Association for Cancer Research $x 1557-3265 $g Roč. 27, č. 2 (2021), s. 575-584
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33082212 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506125828 $b ABA008
- 999 __
- $a ok $b bmc $g 1789937 $s 1163739
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 27 $c 2 $d 575-584 $e 20201020 $i 1557-3265 $m Clinical cancer research $n Clin Cancer Res $x MED00001121
- LZP __
- $a Pubmed-20220425
